Market Overview

UPDATE: ISI Group Reiterates Neutral Rating, Raises PT on Charles River Laboratories on In-Line 4Q12

Share:
Related CRL
Earnings Scheduled For February 10, 2015
ICON Is Now A Strong Buy: Should It Be In Your Portfolio?

In a report published Wednesday, ISI Group reiterated its Neutral rating on Charles River Laboratories (NYSE: CRL), and raised its price target from $40.50 to $43.00.

ISI Group noted, “Charles River posted in-line 4Q'12, with top-line results skewed by a tough comp (recall 4Q'11 had an extra week that contributed 4%), and a bottom-line beat aided by a lower tax rate (discreet tax benefits and higher than expected R&D tax credit in Canada). Pre-clinical services (PCS) segment was the outperformer, up LSD excluding the extra week. Management yet again noted that they continued to see isolated instances of spot price increases, and improving capacity utilization. In RMS, EMD was the standout (>20% growth incl. Accugenix) with the expectation of double-digit growth in the medium term driven by new MCS product launches (Nexus). Models declined mid-single-digits with EU and Asia beginning to show weakness, and Services were down slightly on tough comps. While we are encouraged by signs of green shoots in the PCS segment, tempered outlook in RMS and strategic deal start-up costs (offsetting cost actions) limit earnings power in the medium-term. Given this and current valuation levels, we reiterate our Neutral rating on CRL and are tweaking our PT from $40.50 to $43.00 (14x FY14 EPS; 8x FY14 EBITDA).”

Charles River Laboratories closed on Tuesday at $41.69.

Latest Ratings for CRL

DateFirmActionFromTo
Apr 2015Wells FargoDowngradesMarket PerformUnderperform
Mar 2015SunTrust Robinson HumphreyDowngradesBuyNeutral
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (CRL)

Around the Web, We're Loving...